Hyperforin down-regulates effector function of activated T lymphocytes and shows efficacy against Th1-triggered CNS inflammatory-demyelinating disease

Journal of Leukocyte Biology

Volumn 83, Issue 1, 2008, Pages 212-219

  Cabrelle, Anna ^a,c   Dell'Aica, Isabella ^b   Melchiori, Luca ^b   Carraro, Samuela ^a,c   Brunetta, Enrico ^a,c   Niero, Raffaele ^a,c   Scquizzato, Elisa ^a,c   D'Intino, Giulia ^d   Calzà, Laura ^d   Garbisa, Spiridione ^b,e   Agostini, Carlo ^a,c  

^a Medical School   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^c VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

Experimental allergic encephalomyelitis; Inflammation

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE; GELATINASE B; HYPERFORIN; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

ALLERGIC ENCEPHALITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE ACTIVATION; TH1 CELL; UPREGULATION;

ANIMALS; BICYCLO COMPOUNDS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; PHLOROGLUCINOL; PHYTOHEMAGGLUTININS; RATS; RATS, INBRED LEW; RECEPTORS, CXCR3; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; TERPENES; TH1 CELLS; UP-REGULATION;

ANIMALIA; HYPERICUM PERFORATUM;

EID: 38149002980     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0707469     Document Type: Article

References (41)

1. Chatterjee, S. S., Bhattacharya, S. K., Wonnemann, M., Singer, A., Muller, W. E. (1998) Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 63, 499-510.
2. Laakmann, G., Schule, C., Baghai, T., Kieser, M. St. (1998) John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 (Suppl. 1), 54-59.
3. Singer, A., Wonnemann, M., Muller, W. E. (1999) Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na1. J. Pharmacol. Exp. Ther. 290, 1363-1368.
4. Schempp, C. M., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Kiss, J., Termeer, C. C., Gilb, B., Kaufmann, T., Borner, C., Sleeman, J. P., Simon, J. C. (2002) Inhibition of tumor cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene 21, 1242-1250.
5. Schempp, C. M., Winghofer, B., Ludtke, R., Simon-Haarhaus, B., Schopf, E., Simon, J. C. (2000) Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells. Br. J. Dermatol. 142, 979-984.
6. Albert, D., Zundorf, I., Dingermann, T., Muller, W. E., Steinhilber, D., Werz, O. (2002) Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol. 64, 1767-1775.
7. Schempp, C. M., Hezel, S., Simon, J. C. (2003) Topical treatment of atopic dermatitis with Hypericum cream. A randomized, placebo-controlled, double-blind half-side comparison study. Hautarzt 54, 248-253.
8. Dell'Aica, I., Garbisa, S., Caniato, R. (2007) The renaissance of Hypericum perforatum: bio-medical research catches up with folk medicine. Curr. Bioactive Compounds 3, 109-119.
9. Feisst, C., Werz, O. (2004) Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin. Biochem. Pharmacol. 67, 1531-1539.
10. Quiney, C., Billard, C., Faussat, A. M., Salanoubat, C., Ensaf, A., Nait-Si, Y., Fourneron, J. D., Kolb, J. P. (2006) Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia. Leukemia 20, 491-497.
11. Agostini, C., Cassatella, M., Zambello, R., Trentin, L., Gasperini, S., Perin, A., Piazza, F., Siviero, M., Facco, M., Dziejman, M., Chilosi, M., Qin, S., Luster, A. D., Semenzato, G. (1998) Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J. Immunol. 161, 6413-6420.
12. Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., Marra, F., Romagnani, S., Serio, M., Romagnani, P.. (2003) An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197, 1537-1549.
13. Calzà, L., Giardino, L., Pozza, M., Micera, A., Aloe, L. (1997) Time-course changes of nerve growth factor, corticotropin-releasing hormone, and nitric oxide synthase isoforms and their possible role in the development of inflammatory response in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA 94, 3368-3373.
14. D'Intino, G., Paradisi, M., Fernandez, M., Giuliani, A., Aloe, L., Giardino, L., Calzà, L.. (2005) Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc. Natl. Acad. Sci. USA 102, 3070-3075.
15. Pozza, M., Bettelli, C., Aloe, L., Giardino, L., Calzà, L. (2000) Further evidence for a role of nitric oxide in experimental allergic encephalomyelitis: aminoguanidine treatment modifies its clinical evolution. Brain Res. 855, 39-46.
16. Donà, M., Dell'Aica, I., Pezzato, E., Sartor, L., Calabrese, F., Della Barbera, M., Appendino, G., Borsarini, A., Caniato, R., Garbisa, S. (2004) Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 64, 6225-6232.
17. Dell'Aica, I., Niero, R., Piazza, F., Cabrelle, A., Sartor, L., Colalto, C., Brunetta, E., Lorusso, G., Benelli, R., Albini, A., Calabrese, F., Agostini, C., Garbisa, S. (2007) Hyperforin blocks neutrophil activation of MMP-9, motility and recruitment, and restrains inflammation-triggered angiogenesis and lung fibrosis. J. Pharmacol. Exp. Ther. 321, 492-500.
18. Romagnani, P., Maggi, L., Mazzinghi, B., Cosmi, L., Lasagni, L., Liotta, F., Lazzeri, E., Angeli, R., Rotondi, M., Filì, L., Parronchi, P., Serio, M., Maggi, E., Romagnani, S., Annunziato, F. (2005) CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J. Allergy Clin. Immunol. 116, 1372-1379.
19. Gold, R., Linington, C., Lassmann, H. (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129, 1953-1971.
20. Agnello, D., Lankford, C. S., Bream, J., Morinobu, A., Gadina, M., O'Shea, J. J., Frucht, D. M. (2003) Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J. Clin. Immunol. 23, 147-161.
21. Sallusto, F., Lanzavecchia, A., Mackay, C. R. (1998) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19, 568-574.
22. Kim, C. H., Kunkel, E. J., Boisvert, J., Johnston, B., Campbell, J. J., Genovese, M. C., Greenberg, H. B., Butcher, E. C. (2001) Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J. Clin. Invest. 107, 595-601.
23. Abraham, M., Shapiro, S., Karni, A., Weiner, H. L., Miller, A. (2005) Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J. Neuroimmunol. 163, 157-164.
24. Steinman, L., Zamvil, S. S. (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60, 12-21.
25. Brown, K. A. (2001) Factors modifying the migration of lymphocytes across the blood-brain barrier. Int. Immunopharmacol. 1, 2043-2062.
26. Willenborg, D. O., Staykova, M. A., Cowden, W. B. (1999) Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: a review. J. Neuroimmunol. 100, 21-35.
27. Morini, M., Roccatagliata, L., Dell'Eva, R., Pedemonte, E., Furlan, R., Minghelli, S., Giunti, D., Pfeffer, U., Marchese, M., Noonan, D., Mancardi, G., Albini, A., Uccelli, A. (2004) α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148, 146-153.
28. Aktas, O., Prozorovski, T., Smorodchenko, A., Savaskan, N. E., Lauster, R., Kloetzel, P. M., Infante-Duarte, C., Brocke, S., Zipp, F. (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-κ B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173, 5794-5800.
29. Moreno, B., Hevia, H., Santamaria, M., Sepulcre, J., Munoz, J., Garcia-Trevijano, E. R., Berasain, C., Corrales, F. J., Avila, M. A., Villoslada, P. (2006) Methylthioadenosine reverses brain autoimmune disease. Ann. Neurol. 60, 323-334.
30. Skulina, C., Schmidt, S., Dornmair, K., Babbe, H., Roers, A., Rajewsky, K., Wekerle, H., Hohlfeld, R., Goebels, N. (2004) Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. USA 101, 2428-2433.
31. Rice, G. P., Hartung, H. P., Calabresi, P. A. (2005) Anti-α4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64, 1336-1342.
32. Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., Sandrock, A. W., AFFIRM Investigators (2006) A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910.
33. Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., SENTINEL Investigators (2006) Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923.
34. Greenlee, J. E. (2006) Progressive multifocal leukoencephalopathy in the era of Natalizumab: a review and discussion of the implications. Int. MS J. 13, 100-107.
35. (2006) MS drug back on market under restricted program. FDA Consum. 40, 7.
36. Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., Karin, N. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin. Nature 356, 63-66.
37. Zhu, Y. N., Zhong, X. G., Feng, J. Q., Yang, Y. F., Fu, Y. F., Ni, J., Liu, Q. F., Tang, W., Zhao, W. M., Zuo, J. P. (2006) Periplocoside E inhibits experimental allergic encephalomyelitis by suppressing interleukin 12-dependent CCR5 expression and interferon-γ-dependent CXCR3 expression in T lymphocytes. J. Pharmacol. Exp. Ther. 318, 1153-1162.
38. Liu, L., Huang, D., Matsui, M., He, T. T., Hu, T., Demartino, J., Lu, B., Gerard, C., Ransohoff, R. M. (2006) Severe disease, unaltered leukocyte migration, and reduced IFN-γ production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J. Immunol. 176, 4399-4409.
39. Matsumo, Y., Sakuma, H., Miyakoshi, A., Tsukada, Y., Kohyama, K., Park, I. K., Tanuma, N. (2005) Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. J. Neuroimmunol. 170, 49-61.
40. Marracci, G. H., McKeon, G. P., Marquardt, W. E., Winter, R. W., Riscoe, M. K., Bourdette, D. N. (2004) α Lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res. 78, 362-370.
41. Brundula, V., Rewcastle, N. B., Metz, L. M., Bernard, C. C., Yong, V. W. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125, 1297-1308.